Precision DL, a deep learning-based software which will be available on GE HealthCare’s Omni Legend PET/CT device, reportedly increases the detectability of small, low-contrast lesions by 42 percent.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Precision DL (GE HealthCare), an artificial intelligence (AI)-enabled image processing software, which may offer significant improvements in contrast-to-noise ratio (CNR), the accuracy of feature quantification, and the diagnosis of small lesions on positron emission tomography (PET)/ computed tomography (CT).
Engineered with a deep neural network trained on thousands of images via multiple reconstruction methods, Precision DL will be accessible through the Omni Legend PET/CT device (GE HealthCare).
The company said Precision DL offers a variety of imaging enhancement benefits including:
• an average 42 percent increase in the detection of small, low-contrast lesions;
• an average 23 percent improvement in CNR; and
• a 14 percent improvement in the accuracy of feature quantification.
“Precision DL enhances image quality – enabling us to spot small lesions, including on images obtained with very low dose injections and short bedtimes, to potentially start treatment and monitoring early, which might result in improved outcomes,” noted Flavio Forrer, M.D., Ph.D., the chairman of nuclear medicine at Kantonsspital St. Gallen in Switzerland.
(Editor’s note: For related content, see “GE Healthcare Launches Omni Legend PET/CT System at EANM Congress.”)
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.